Vironexis

Vironexis has licensed, from Nationwide Children’s Hospital, exclusive worldwide commercial rights to a patented revolutionary immunotherapy for broad forms of cancer, including pediatric and adult blood and solid organ malignancies. It is led by CEO Samit Varma, a 20-year serial entrepreneur and venture capital investor and two of the most prominent and successful scientists in the field, including the founder and Chief Science Officer of the most successful gene therapy in the world, Zolgensma (now owned by Novartis). Recent preclinical studies in mice have produced astounding results and this round of funding will support the human clinical trials, which are set to begin next year. Should the drug work as intended, they can effectively train the human immune system to recognize tumors and cancer cells as foreign bodies, rather than friendly cells. This allows the natural immune system to work against the cancer cells, potentially for the full life of a the person.